Abstract
The understanding of polypoidal choroidal vasculopathy has evolved rapidly in the past three decades. The hallmark of the disease is the presence of typical hyperfluorescent nodules in the early phase of indocyanine green angiography. Although the classical clinical presentation is recurrent serosanguinous detachment of the retinal pigment epithelium, it may present with clinical features indistinguishable from exudative age-related macular degeneration secondary to choroidal neovascularization. Some cases may present initially with submacular haemorrhage, but later with features of exudative age-related macular degeneration. Studying the associated network of vessels using confocal scanning laser ophthalmoscopy indocyanine green dynamic angiography revealed in many cases feeder vessels, branching pattern, and leakage similar to choroidal neovascularization. Owing to the overlap of clinical and angiographic features, it may be considered as a vascular subtype of exudative age-related macular degeneration. However, having seemingly better natural history, better response to photodynamic therapy, and incomplete response to anti-vascular endothelial growth factor therapy suggests that it should be studied as a separate entity from choroidal neovascularization. Combining angio-occlusion of the polyps using photodynamic therapy and anti-permeability effect of anti-vascular endothelial growth factor therapy on the branching vascular network may provide a synergistic effect. We await the result of EVEREST trial, a multi-centre randomized controlled trial comparing photodynamic therapy, with or without ranibizumab, with ranibizumab monotherapy.
Introduction
Polypoidal choroidal vasculopathy (PCV) is an interesting, multi-faceted disease. First described by Yannuzzi in 1980, it came to be known by various terms such as posterior uveal bleeding syndrome and multiple recurrent serosanguinous retinal pigment epithelial detachment in black women, until Yannuzzi termed it idiopathic polypoidal choroidal vasculopathy in 1990.1 Over the next two decades, the understanding of this condition has evolved rapidly.
Clinical presentation
Although a typical case presents with recurrent acute submacular haemorrhage or serosanguinous pigment epithelial detachments (PED),2 it is now known that many present with features similar to exudative age-related macular degeneration (AMD), namely, submacular exudation, intra-retinal thickening, serous PED,3 fibrovascular PED, subretinal fluid collection, and disciform scar.4 Some present with serous sensory retinal detachment, clinically indistinguishable from central serous chorioretinopathy (CSCR).5 Still others present with patchy areas of retinal pigment epithelial (RPE) atrophy associated with intra-retinal pigmentary disturbance, often associated with visible, orange subretinal nodules (Figure 1). Rarely, PCV may present with massive spontaneous suprachoroidal haemorrhage.6
Although significant drusen in the affected or fellow eye is less common among PCV patients compared to exudative AMD due to choroidal neovascularization (CNV), their presence is not uncommon, ranging from 26.77 to 33%.8
Fundus angiography
The unifying diagnostic feature in this myriad of presentations is the presence of subretinal nodular hyperfluorescence (the polyps) in fundus indocyanine green angiography (ICGA). These polyps typically appear within the first 5 min of ICGA, and persist into the late phase. In addition, at least one of the following criteria must be fulfilled to be diagnostic of PCV: (1) presence of hypofluorescent halo around the lesion, (2) presence of pulsation, (3) association with a branching vascular network (BVN), (4) correspondence to an orange-red nodule in fundus photographs, (5) a nodular appearance, rather than a flat lesion, when viewed in stereo pairs, or (6) associated with massive submacular haemorrhage (criteria from the Central Reading Centre, EVEREST trial).
The polyps may be solitary (arbitrarily defined as one or two polyps), or multiple. If multiple, the polyps may be arranged in a ring (or ‘whorl’ pattern) or cluster (or ‘bunch of grapes’). It has been suggested that latter pattern carries a poorer prognosis.9 A similar classification has been proposed by Cackett et al.10
Although the earlier description of a typical PCV is peri-papillary in location, it is now known that the majority of Asian cases are in the macula.11 Although there is no unified classification system for the location of PCV, the lesion is usually described to be peri-papillary if more than half of the lesion (polyp and BVN) in ICGA is located within 1500 μm of the disc margin, and macular if more than half of the lesion is within 6000 μm diameter of the centre of fovea avascular zone excluding the peri-papillary zone. It is described to be extra-macular if more than half of the lesion is located outside the above-mentioned two zones (Figure 2). Extra-macular or peripheral PCV is uncommon, but has been reported.12 If the lesion straddles over all the three regions, and none of the zone contains more than half of the lesion, or if there is more than one non-contiguous lesion, it is described as ‘multi-location’.
Not all focal ICG hyperfluorescences are due to PCV. Common conditions that have been misdiagnosed as PCV (‘pseudo-PCV’) include: stage 1 retinal angiomatous proliferation, retinal macro-aneurysm, focal RPE defect associated with a choroidal vascular knuckle. It is therefore important to study the still frames of the angiogram in stereo, and to study the earliest phase of ICGA carefully, preferably dynamically.
Fundus fluorescein angiographic (FFA) features of PCV depend on the pathological process of the disease rather than the causative vascular lesions. The majority of cases show FFA findings similar to occult CNV, typically pure occult lesions. Rarely, the polyps are visible in FFA. ICGA should be considered in patients with occult CNV,13 particularly among patients of pigmented races.
Demography
Polypoidal choroidal vasculopathy tends to present at a younger age compared to exudative AMD.14 The mean age of diagnosis is about 65 years, with a slight male preponderance.15 Although initially reported among black women, recent reports have also shown that it is a common vascular subtype of exudative AMD among East Asians. PCV accounts for about ¼ to ½ of cases manifesting as exudative AMD in Asia, compared to approximately 10% of Caucasian population (Table 1 ).
Pathogenesis
Although the pathogenesis of this condition is largely unknown, some anecdotal case reports point to the possible association with systemic cardiovascular risk factors, such as hypertension16 and elevated plasma viscosity.17
Histopathology studies are few. Lafaut et al18 found sub-RPE, intra-Bruch fibrovascular membrane with saccular aneurysmal vascular dilation. Terasaki et al19 reported a specimen showing intra-Bruch dilated, thin-walled vessels without pericytes, that stained positive for vascular endothelial growth factor (VEGF) in the endothelial cells, suggesting it is neovascular in nature. Similarly, Matsuoka et al20 found expression of VEGF and pigment epithelial-derived factor in both specimen of CNV and PCV, again suggesting neovascular nature of the latter condition. Likewise, Nakajima et al21 reported two cases of PCV with associated CNV when examined under light microscopy.
Okubo et al,22 however, reported a histopathological specimen that showed atherosclerosis of intra-choroidal arteriole, with dilation of venule at the crossing, suggesting that inner choroidal venular compression and stasis may be the causative mechanism. Likewise, Kuroiwa et al23 observed changes mainly in the large choroidal arterioles, showing disruption of inner elastic layer, and deposition of basement membrane-like material and collagen in the vessel wall, suggesting that atherosclerosis of inner choroidal arterioles may be important. Similarly, Nakashizuka et al24 reported hyalinization of choroidal vasculature, again underpinning the role of atherosclerosis in PCV. In the same study, however, they found no VEGF staining of the vascular endothelium of the polyps, in contrast to previous reports.
In addition, Sasahara et al25 found that choroidal hyperpermeability, a common ICGA finding of CSCR, occurred in 10% of a case series of PCV. As PCV may also present as CSCR, the causative relationship between choroidal hyperpermeability, CSCR, and PCV is currently unclear.
Natural history
There is paucity in natural history data of PCV. Clinical experience suggests that PCV carries a better prognosis than exudative AMD due to CNV. Uyama et al9 reported a case series of 14 eyes of 12 patients with ICG-proven PCV. Half of the patients presenting with initial VA of 20/32 or better maintained their vision without treatment, despite episodes of recurrent submacular haemorrhage. For the other half with poorer presenting VA, about 70% avoided moderate visual loss with follow-up durations of 3–5 years. Sho et al,26 in a cross-sectional study of 418 eyes of presumed exudative AMD, found that 35% of PCV, as compared with 53% of exudative AMD, was associated with significantly reduced vision of 20/100 or worse.
Treatment
Polypoidal choroidal vasculopathy responds very well to angio-occlusive therapy using verteporfin photodynamic therapy (PDT). More than 15 interventional case series of verteporfin PDT for PCV had been published. Selected studies are summarized and presented in Table 2 . Most studies quoted 1-year avoidance of moderate visual loss of more than 80% and three-line visual improvement of 25–55%. The response of PCV to PDT is significantly better than CNV in both visual acuity27 and electrophysiology outcome,28 especially among cases presenting with serous PED.29
However, clinical experience suggests that a subgroup of PCV patients respond poorly to verteporfin PDT monotherapy. Persistent or recurrent macular oedema is known to occur despite successful occlusion of all visible polyps. These cases were initially thought to be due to secondary CNV. Combining FFA, dynamic ICGA, and optical coherence tomographic (OCT) studies of such cases suggests that most cases are due to leakage from persistent BVN, with or without vascular remodeling, as evident by the constant location of the feeder vessel in-growth site before and after PDT (Figure 3).
Focal thermal ablation of polyps using ICGA-guided laser photocoagulation is a treatment option for PCV. However, current reports showed conflicting outcomes. Lee showed that visual stabilization can be achieved in 75% of cases treated by this modality. Yuzawa et al30 reported that treating the whole lesion (polyps and network vessels) seemed to produce better results than treating the polyps alone. In the latter, more than half (54%) experienced decreased visual acuity due to persistent or recurrent leakage, presumably due to untreated vascular network. In a non-randomized comparative study, Kwok et al15 found that cases treated with thermal laser photocoagulation to the polyps showed a trend of better visual outcome compared with untreated cases, though the difference was not statistically significant. Vilaplana et al,31 however, reported poor visual outcome in a small case series. In the authors’ opinion, ICGA-guided focal thermal ablation of polyps should be reserved for milder cases with inactive vascular network.
Branching vascular network of PCV
Although the diagnosis of PCV focuses our attention on the polyps, the authors believe that studying the associated vascular network may explain the behaviour and response to treatment of these lesions. The vascular network was termed BVN by Spaide et al.32
Branching vascular network typically persists after PDT, even when the polyps showed complete regression.33, 34 Although most BVNs stay quiescent for long periods of time, they are by no means passive channels. Some sprout new polyps at its terminal branches (recurrence).35 A number show continued leakage even after angiographically proven complete polyp ablation (persistence). Still others remain quiescent for months, then start to leak without any visible new polyps (reactivation).
The origin and location of these network vessels remain controversial. Some believe that they are sub-RPE in location, representing a type of CNV,36 whereas others believe they are intra-choroidal.37 Using a prototype of spectral domain OCT, Ojima et al38 were able to identify both BVN and vascular polyp as hyper-reflectivity between RPE and Bruch's membrane, in the same tissue plane as CNV.
With the advent of confocal scanning laser ophthalmoscopy, coupled with digital dynamic ICGA (CSLO-ICGA), these network vessels are much better imaged than flash-based ICG angiography, especially the first 30 s after dye injection. Studying CSLO-ICGA, Yuzawa et al39 observed that in some cases the BVN showed pulsatile flow, suggesting that they emanate from inner choroidal arterioles. The authors concluded that there may be two types of BVN, one represents intra-choroidal vascular abnormality (‘PCV in the narrow sense’), the other represents neovascularization (‘polypoidal CNV’) that grows rapidly in the sub-RPE space.
Dynamic CSLO-ICGA also allows the identification of feeder vessels. In many cases, the vascular tree of the BVN is traceable to a single feeder vessel, possibly representing the vascular in-growth site crossing the Bruch's membrane.40 If it is also associated with fluorescein leakage (as imaged by FFA) and overlying retinal thickening (as imaged by OCT, and observed clinically), these lesions look angiographically and behave clinically like CNV (CNV-like BVN). In a retrospective study of 52 consecutive cases of PCV, the authors found CNV-like BVN in one-third of cases (data presented at International Spectralis Meeting, Nice, 2008).
Anti-vascular endothelial growth factor therapy for PCV
Intra-vitreal anti-VEGF therapy has revolutionized the treatment for exudative AMD due to CNV. Would PCV, in particular those with CNV-like BVN, respond to anti-VEGF treatment?
Tong et al41 reported increased aqueous level of VEGF in patients with PCV, though at a lower level than eyes with exudative AMD with CNV. As mentioned above, Terasaki et al19 and Matsuoko et al20 reported increased VEGF staining and expression on the vascular endothelium of PCV specimens. Initial clinical experience suggests that PCV respond well to anti-VEGF therapy, with rapid resolution of retinal thickening and exudate accumulation,42, 43 and increase in vision.44
However, both Gomi et al45 and Lai et al46 reported that although anti-VEGF monotherapy reduces macular thickness and improved vision in patients with PCV, the majority of the polyps remained. The data may explain anecdotal clinical cases of late recurrent massive submacular haemorrhage of patients with PCV despite initial ‘successful’ treatment with anti-VEGF monotherapy.
Likewise, Cho et al47 reported 12 cases of presumed exudative AMD not responding to anti-VEGF monotherapy of at least 6 months’ duration. PCV was diagnosed when they were later imaged with ICGA. PDT subsequently performed achieved complete resolution in 9 of 12 cases, and partial resolution in the remaining 3 cases.
Combination therapy for PCV
Understanding of the action of verteporfin PDT on polyp closure and the response of BVN leakage to anti-VEGF therapy give rise intuitively to the suggestion of combination therapy for PCV treatment. The primary rationale of proposing combination therapy for PCV is different from those proposed for exudative AMD due to CNV. In the latter condition, combination therapy aims to reduce the number of anti-VEGF re-injections through photothrombosis effect of verteporfin PDT on the CNV vasculature, and at the same time, balancing the VEGF upregulation effect of photothrombosis. For PCV, combining photothrombosis of the polyps (with the associated vascular network) with anti-vasoproliferative and anti-permeability therapy targeting the BVN aims to achieve synergistic effect by targeting different component lesions of PCV.
For this reason, the EVEREST trial was convened. It was the first randomized controlled trial investigating whether verteporfin therapy, either as monotherapy or in combination with intra-vitreal ranibizumab, is more efficacious than ranibizumab monotherapy in achieving complete polyp regression (primary outcome) as assessed by CSLO-ICGA. The secondary outcomes include visual acuity, as measured by Early Treatment of Diabetic Retinopathy Study chart, and central retinal thickness as measured by OCT. Involving seven sites in five Asian countries, the trial recruited 61 patients with symptomatic PCV with visual acuity between 24 and 73 letters on the Early Treatment of Diabetic Retinopathy Study chart. Cases were included only if the CSLO-ICGA is assessed to be typical PCV by a reading centre (Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore). Subjects were randomly assigned to three treatment arms in 1 : 1 :1 ratio: (1) verteporfin PDT and sham injection, (2) ranibizumab intra-vitreal injections and sham PDT, and (3) combined verteporfin PDT and intra-vitreal ranibizumab injections. Results will become publicly available in 2010.
Conclusion
The understanding of PCV as a disease entity has undergone rapid evolution in the past three decades. Though differentiated by the specific features in ICGA, current understanding of the disease suggests significant overlap with exudative AMD due to CNV. Present in about one-third of Asian and one-tenth of Caucasian patients with exudative AMD, it is reasonable to be considered as a vascular subtype of exudative AMD. Seemingly better natural history, better response to PDT, and seemingly incomplete response to anti-VEGF suggest that it should be studied as a separate entity from CNV. For Caucasian patients, ICGA may be important in cases of anti-VEGF non-responders to elucidate the diagnosis of PCV. In Asian patients, ICGA may be useful for most cases of exudative AMD with occult CNV (on FFA) for proper vascular subtyping. About one-third of cases of PCV behaves angiographically and clinically as CNV, even after successful polyp ablation with focal photocoagulation of the polyps or ICGA-guided PDT of the whole lesion. Combination therapy should be considered in these cases, with evidence-based results pending from the EVEREST trial.
Conflict of interest
TH Lim had received travel support from Novartis and Heidelberg Engineering.
References
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B . Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10 (1): 1–8.
Ahuja RM, Stanga PE, Vingerling JR, Reck AC, Bird AC . Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. Br J Ophthalmol 2000; 84 (5): 479–484.
Pauleikhoff D, Löffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240 (7): 533–538.
Chuah CT, Chee C . Idiopathic polypoidal choroidal vasculopathy as a cause of a disciform macular scar. Clin Experiment Ophthalmol 2003; 31 (2): 163–165.
Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000; 107 (4): 767–777.
Tan CS, Wong HT, Lim BA, Hee OK, Lim TH . Polypoidal choroidal vasculopathy causing massive suprachoroidal haemorrhage. Eye 2007; 21 (1): 132–133.
Scassellati-Sforzolini B, Mariotti C, Bryan R, Yannuzzi LA, Giuliani M, Giovannini A . Polypoidal choroidal vasculopathy in Italy. Retina 2001; 21 (2): 121–125.
Iwama D, Tsujikawa A, Sasahara M, Hirami Y, Tamura H, Yoshimura N . Polypoidal choroidal vasculopathy with drusen. Jpn J Ophthalmol 2008; 52 (2): 116–121.
Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002; 133 (5): 639–648.
Cackett P, Wong D, Yeo I . A classification system for polypoidal choroidal vasculopathy. Retina 2009; 29 (2): 187–191.
Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999; 117 (8): 1035–1042.
Akman A, Akbatur H, Yilmaz G, Aydin P . Peripheral idiopathic polypoidal choroidal vasculopathy. Eye 2000; 14 ( Part 4): 680–681.
Stanga PE, Lim JI, Hamilton P . Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology 2003; 110 (1): 15–21.
Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 1999; 117 (11): 1503–1510.
Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS . Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002; 86 (8): 892–897.
Ross RD, Gitter KA, Cohen G, Schomaker KS . Idiopathic polypoidal choroidal vasculopathy associated with retinal arterial macroaneurysm and hypertensive retinopathy. Retina 1996; 16 (2): 105–111.
Lip PL, Hope-Ross MW, Gibson JM . Idiopathic polypoidal choroidal vasculopathy: a disease with diverse clinical spectrum and systemic associations. Eye 2000; 14 (Part 5): 695–700.
Lafaut BA, Aisenbrey S, Van den Broecke C, Bartz-Schmidt KU, Heimann K . Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlation. Retina 2000; 20 (6): 650–654.
Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T . Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol 2002; 86 (3): 321–327.
Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M . Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88 (6): 809–815.
Nakajima M, Yuzawa M, Shimada H, Mori R . Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2004; 48 (3): 249–255.
Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N . Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002; 86 (10): 1093–1098.
Kuroiwa S, Tateiwa H, Hisatomi T, Ishibashi T, Yoshimura N . Pathological features of surgically excised polypoidal choroidal vasculopathy membranes. Clin Experiment Ophthalmol 2004; 32 (3): 297–302.
Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 2008; 49 (11): 4729–4737.
Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 2006; 142 (4): 601–607.
Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003; 121 (10): 1392–1396.
Honda S, Imai H, Yamashiro K, Kurimoto Y, Kanamori-Matsui N, Kagotani Y et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo Prefecture, Japan. Ophthalmologica 2009; 223 (5): 333–338.
Imai H, Honda S, Nakanishi Y, Yamamoto H, Tsukahara Y, Negi A . Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2006; 90 (12): 1524–1530.
Saito M, Iida T, Nagayama D . Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92 (12): 1642–1647.
Yuzawa M, Mori R, Haruyama M . A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003; 47 (4): 379–384.
Vilaplana D, Castilla M, Poposki V . Laser photocoagulation in idiopathic polypoidal choroidal vasculopathy. Over one year follow-up. Arch Soc Esp Oftalmol 2005; 80 (10): 597–602.
Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA . Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995; 15 (2): 100–110.
Akaza E, Mori R, Yuzawa M . Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008; 28 (5): 717–722.
Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y . Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008; 92 (7): 936–940.
Lee WK, Lee PY, Lee SK . Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence. Jpn J Ophthalmol 2008; 52 (2): 108–115.
Tateiwa H, Kuroiwa S, Gaun S, Arai J, Yoshimura N . Polypoidal choroidal vasculopathy with large vascular network. Graefes Arch Clin Exp Ophthalmol 2002; 240 (5): 354–361.
Iijima H, Imai M, Gohdo T, Tsukahara S . Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 1999; 127 (3): 301–305.
Ojima Y, Hangai M, Sakamoto A, Tsujikawa A, Otani A, Tamura H et al. Improved visualization of polypoidal choroidal vasculopathy lesions using spectral-domain optical coherence tomography. Retina 2009; 29 (1): 52–59.
Yuzawa M, Mori R, Kawamura A . The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol 2005; 89 (5): 602–607.
Costa RA, Navajas EV, Farah ME, Calucci D, Cardillo JA, Scott IU . Polypoidal choroidal vasculopathy: angiographic characterization of the network vascular elements and a new treatment paradigm. Prog Retin Eye Res 2005; 24 (5): 560–586.
Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141 (3): 456–462.
Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW . Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009; 223 (2): 85–92.
Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, Leila M, Garcia-Sanchez J . Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 2008; 18 (4): 645–648.
Lee SY, Kim JG, Joe SG, Chung H, Yoon YH . The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008; 22 (2): 92–99.
Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92 (1): 70–73.
Lai TY, Chan WM, Liu DT, Luk FO, Lam DS . Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92 (5): 661–666.
Cho M, Barbazetto IA, Freund KB . Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009; 148 (1): 70–78.e1.
Ladas ID, Rouvas AA, Moschos MM, Synodinos EE, Karagiannis DA, Koutsandrea CN . Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye 2004; 18 (5): 455–459.
Wen F, Chen C, Wu D, Li H . Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol 2004; 242 (8): 625–629.
Maruko I, Iida T, Saito M, Nagayama D, Saito K . Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144 (1): 15–22.
Liu Y, Wen F, Huang S, Luo G, Yan H, Sun Z et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 2007; 245 (10): 1441–1445.
Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW . Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol 2008; 52 (1): 57–62.
Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111 (8): 1576–1584.
Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG . Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005; 243 (10): 973–979.
Mauget-Faÿsse M, Quaranta-El Maftouhi M, De La Marnièrre E, Leys A . Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol 2006; 16 (5): 695–704.
Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R . Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007; 51 (4): 270–277.
Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA . Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007; 27 (7): 825–831.
Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007; 144 (1): 7–14.
Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115 (1): 141–146.
Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008; 146 (4): 513–519.
Author information
Authors and Affiliations
Corresponding author
Additional information
The paper was presented at Cambridge Ophthalmology Symposium, September 2009
Rights and permissions
About this article
Cite this article
Lim, T., Laude, A. & Tan, C. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye 24, 483–490 (2010). https://doi.org/10.1038/eye.2009.323
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2009.323
Keywords
This article is cited by
-
Randomized controlled trials in central serous chorioretinopathy: A review
Eye (2023)
-
Hyaluronidase-1-mediated glycocalyx impairment underlies endothelial abnormalities in polypoidal choroidal vasculopathy
BMC Biology (2022)
-
Optical coherence tomography in diagnosing polypoidal choroidal vasculopathy. Looking into the future: a systematic review and meta-analysis
International Journal of Retina and Vitreous (2022)
-
The comparison of spectral domain optical coherence tomography and indocyanine green angiography in the diagnosis of polypoidal choroidal vasculopathy
International Ophthalmology (2021)
-
Early changes of vascular lesions and responses to combined photodynamic therapy in patients with polypoidal choroidal vasculopathy
International Ophthalmology (2020)